Provision of end-to-end digital histopathology pathway service with integrated AI diagnostic support and NHS reporting

University Hospitals Plymouth NHS Trust is releasing this Intended Approach Notice as per the NHS Provider Selection Regime (PSR) using the Most Suitable Provider route.

As per schedule 5 under Regulation 10(3), please see below the required information.

1. University Hospitals Plymouth NHS Trust is intending to follow the Most Suitable Provider Process to award a contract.
2. The contract title - Provision of end-to-end digital histopathology pathway service with integrated AI diagnostic support and NHS reporting

The contract reference - C407455

3. Provision of fully integrated cancer diagnostic services, focused on the prostate cancer pathway – from biopsy room, digital request and logistics through controlled laboratory processing, AI-supported diagnosis, and visual structured reporting - delivered within guaranteed timeframes through a unified digital ecosystem under NHS-led clinical responsibility. The service enables structured data capture to support ongoing hospital process improvement, research, and performance monitoring. This procurement will be conducted under the NHS Provider Selection Regime (PSR) using the Most Suitable Provider route.

CPV Code - 85111800

4. The key decision makers involved in this procurement process are Rob Archer (Cellular & Anatomical Pathology Operations Manager), Mark Austin (Category Manager for Clinical Support)